OncoMatch/Clinical Trials/NCT06980532
Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer
Is NCT06980532 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Glumetinib Combined with Fruquintinib for metastatic colorectal cancer.
Treatment: Glumetinib Combined with Fruquintinib — Glumetinib combined withFruquintinib in the treatment of MET amplification or protein overexpression in third-line unresectable metastatic colorectal cancer: evaluation of efficacy and safety
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: MET amplification (FISH MET GCN≥4 or MET/CEP7≥1.8; Or NGS, ≥20% of tumor cells, ≥200X sequencing depth, GCN≥4)
Have MET amplification (FISH MET GCN≥4 or MET/CEP7≥1.8; Or NGS, ≥20% of tumor cells, ≥200X sequencing depth, GCN≥4)
Required: MET overexpression (IHC 3+ (≥50% of tumor cells strongly positive) or 2+ (≥50% of tumor cells moderately/strongly positive and <50% strongly positive))
overexpression (IHC, 3+(≥50% of tumor cells are strongly positive) or 2+ (≥50% of tumor cells are moderately positive/strongly positive and < 50% of tumor cells are strongly positive); Immunohistochemistry (IHC) detection showed that the MET protein overexpression in the subjects was 3+(strongly positive in ≥50% of tumor cells) or 2+ (positive in ≥50% of tumor cells/weakly positive and strongly positive in < 50% of tumor cells)
Allowed: BRAF mutation
Patients with unresectable metastatic colorectal cancer whose BRAF gene test is mutant and who have not received BRAF inhibitors /MEK inhibitors
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard anti-tumor regimens
Imaging confirmed progression after previous two-line standard anti-tumor regimens
Cannot have received: MET inhibitor
Have received MET inhibitor treatment in the past
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, platelet count ≥75×10^9/L, hemoglobin 80 g/L, WBC ≥3.0×10^9/L (no transfusion, blood products, or hematopoietic stimulating factor within 14 days)
Kidney function
Serum creatinine ≤1.5x ULN or creatinine clearance rate ≥50mL/min
Liver function
AST and ALT ≤2.5x ULN (≤5x ULN with liver invasion); serum total bilirubin ≤2x ULN (≤2.5x ULN with liver invasion)
Absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥75×10^9/L and hemoglobin 80 g/L, white blood cell count (WBC) ≥3.0×10^9/L (corrected by no blood transfusion, no blood products, no use of granulocyte colony-stimulating factor or other hematopoietic stimulating factor within 14 days before laboratory tests); Liver and kidney functions: Serum creatinine ≤1.5 times the upper limit of normal value or creatinine clearance rate ≥50mL/min; AST and ALT ≤2.5 times the upper limit of normal values (for patients with liver invasion, ≤5 times the upper limit of normal values); Serum total bilirubin ≤2 times the upper limit of normal value (for patients with liver invasion ≤2.5 times the upper limit of normal value); The activated partial thromboplastin time (APTT), International normalized ratio (INR), and prothrombin time (PT) are ≤1.5 times the normal upper limit value.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify